Short communication: Contribution of the immunovirological state and traditional cardiovascular risk factors to low HDL-cholesterol in HIV patients

AIDS Research and Human Retroviruses

Volumn 26, Issue 11, 2010, Pages 1167-1170

  Palacios, R ^a   Puerta, S ^a   Orihuela, F ^b   Olalla, J ^c   Roldan J ^d   Grana, M ^e   Marquez M ^a   Colmenero, J D ^b   Santos, J ^a   Gallego, M ^a   Ruiz, J ^a   Nino E ^a   Castano M ^b   Jimenez Onate F ^b   Delgado, M ^b   del Arco, A ^c   de la Torre, J ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL COSTA DEL SOL   (Spain)

^d HOSPITAL DE ANTEQUERA   (Spain)

^e Hospital de la Serrania   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING; SPAIN; VIRUS DETECTION; VIRUS LOAD;

EID: 78649279923     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0284     Document Type: Article

References (26)

1. Santos J, Palacios R, González M, Ruiz J, and Márquez M: Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Nétar Study). Int J STD AIDS 2005;16:677-680.
2. Friis-Möller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, et al. and the DAD study group: C: Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-1193.
3. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, et al.: Ischemic heart disease in HIV-infected and HIV-uninfected individuals: A populationbased cohort study. Clin Infect Dis 2007;44:1625-1631.
4. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P, et al.: Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation 2008;118:e20-28.
5. Ansell BJ, Watson KE, Fogelman AM, Navab M, and Fonarow GC: High density lipoprotein function recent advances. J Am Coll Cardiol 2005;46:1792-1798.
6. Rose H, Woolley A, Hoy J, Dart A, Bryant B, Mijch A, et al.: HIV infection and high-density lipoprotein: The effect of the disease vs the effect of treatment. Metabolism 2006;55:90-95.
7. Rose H, Hoy J, Woolley A, Tchoua U, Bukrinsky M, Dart A, et al.: HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008;199:79-86.
8. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, et al. for the INSIGHT SMART Study Group: Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; available on line: doi:10.1016/j.atherosclerosis.2009.05.001.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486-2497.
10. Friedewald WT, Levy RI, and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
11. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, et al.: Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006;43:458-466.
12. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, Gimeno JL, et al.: Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care 2005;28:132-137.
13. Bernal E, Masiá M, Padilla S, and Gutiérrez F: High-density lipoprotein cholesterol in HIV-infected patients: Evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDs 2008;22:569-575.
14. Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, et al.: The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D. E. S. I. R. study. Diabetes Metab 2003;29:526-532.
15. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr., Williams K, and Haffner SM: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003;52:2160-2167.
16. Sánchez-Chaparro MA, Román-García J, Calvo-Bonacho E, Gómez-Larios T, Fernández-Meseguer A, Sáinz- Gutiérrez JC, et al.: Prevalence of cardiovascular risk factors in the Spanish working population. Rev Esp Cardiol 2006;59:421-430.
17. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, et al.: Effects of HIV disease on lipid, glucose and insulin levels: Results from a large antiretroviralnaïve cohort. HIV Med 2005;6:114-121.
18. Philips AN, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman WJ, et al.: Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: Exploratory analysis from the SMART trial. Antivir Ther 2008;13:177-187.
19. Palacios R, Santos J, Ruiz J, González M, Valdivielso P, Márquez M, and González-Santos P: Short-term lipid changes associated with highly active antiretroviral therapy in näive HIV-infected patients. J Acquir Immune Defic Syndr 2003;34:249-251.
20. Ridler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-2982.
21. Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, et al.: Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007;45:34-42.
22. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. and the Atlantic Study Team: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;1518:2407-2414.
23. Negredo E, Ribalta J, Paredes R, Ferré R, Sirera G, Ruiz L, et al.: Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002;16:1383-1389.
24. Franssen R, Sankatsing RR, Hassink E, Hutten B, Ackermans MT, Brinkman K, et al.: Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol 2009;29:1336-1341.
25. Avogaro P, Ghiselli G, Soldan S, and Bittolo BG: Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia. Atherosclerosis 1992;92:79-86.
26. Craig WY, Palomaki GE, and Haddow JE: Cigarette smoking and serum lipid and lipoprotein concentrations: An analysis of published data. Br Med J 1989;298:784-788.